Navigation Links
BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
Date:4/8/2011

NEWARK, N.J., April 8, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced the appointment of Michael D. Francis, J.D., as a new member to its Board of Directors.

Mr. Francis is a graduate of the Wharton School of Business, University of Pennsylvania and received his Juris Doctorate from Rutgers University, School of Law. He has been an attorney in the state of New Jersey since 1971. Throughout his career, Mr. Francis has held numerous board appointments within the health care industry. From 1978 to present, he has been Director of the Daughters of Israel Geriatric Center, and held former posts as Treasurer, President and Vice President.

Previously, Mr. Francis was Chairman of Board for the following organizations: Newark Beth Israel Medical Center from 1980 to 1998; United Way of Essex and West Hudson from 1986 to 1990; and Beth Health Care Foundation from 1988 to 1999. His executive management experience includes Chairman and CEO of the Planned Companies from 1989 to 2008 and President of All State Cleaning Contractors from 1971 to 1985. He was CEO of Atlantic Building Maintenance Corp. from 1971 to 1985, where he was responsible for managing the aforementioned companies, providing multifaceted building maintenance services with in excess of 1,000 employees.  

"We are honored to welcome Mr. Francis to our Board. He is not only a significant investor but also a long time advisor to the company and advocate of our innovative technology.  He is an experienced successful entrepreneur and health care advocate, who has won numerous awards by serving his local community and government," stated Stephen J. Browand, Chairman and CEO of BioNeutral Group, Inc. who went on to say, "His legal acumen and health care advisory experience will provide additional, valuable insight as we move forward with commercializing our newly EPA-approved Ygiene® Hospital-Gra
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
2. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
6. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
8. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
9. BioNeutral Group to Receive Economic Development Incentives
10. BioNeutral Group Secures Three Initial Trial Orders for its Ogieneā„¢ Odor Neutralizer & Multi-Purpose Cleaner Product Line
11. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/25/2015)... 2015  PureTech, a science-driven healthcare company seeking to ... ways, announced today that Dame Marjorie Scardino , ... Pearson, has been appointed to PureTech,s Board of Directors ... current Board member Joi Ito , MIT Media ... Ben Shapiro , PureTech,s outgoing Chairman and co-founder, former ...
(Date:5/22/2015)... DUBLIN , May 22, 2015  Actavis plc ... of the U.S. Court of Appeals for the Second ... 2014 preliminary injunction requiring the Company to continue distribution ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   ... uphold this ruling, we intend to continue our strong ...
(Date:5/22/2015)... DALLAS , May 22, 2015 Baylor ... and the Translational Genomics Research Institute (TGen) in ... that will focus on accelerating early detection and treatments for ... science of both institutions will lead to new clinical trials ... therapies – bridging the gap from bench to bedside across ...
Breaking Biology Technology:AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4
... on InterMune Phase 3 CAPACITY Program - ... patient retention rate in CAPACITY -, BRISBANE, Calif., Oct. ... on October 16, 2008, the Japanese,Ministry of Health, Labor and ... & Co. Ltd. to market pirfenidone,for the treatment of patients ...
... million to create a leading center for medical excellence; ... ... Fueled by a grant from the John S.,and James L. Knight ... the BioInnovation Institute in,Akron -- a unique collaboration that will expand ...
... ISTO Technologies, Inc., a privately,held orthobiologics company, ... injectable cell-based therapy for spinal disc,repair. The data ... Annual,Meeting of the North American Spine Society. Studies ... (UCSF) Department of Orthopedics,were designed to investigate potential ...
Cached Biology Technology:InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4BioInnovation Institute in Akron Launched 2BioInnovation Institute in Akron Launched 3BioInnovation Institute in Akron Launched 4Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society 2
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... and Prevention (CDC) today released new infection control ... Carbapenemase (KPC)-Producing Organisms, one of the ... shown that infections with these highly resistant bacteria ... In Guidance for Control of Infections with ...
... in German . The gene Myc is ... division. It causes the production of a protein which, as ... % of all human genes. When this gene mutates to ... Thereby the gene plays a decisive role in the development ...
... 18, 2009) Epidemiologists and computer scientists at the ... low-cost, green technology for automatically tracking the use of ... they exit patient rooms. This novel method of ... control in hospitals, was released today at the annual ...
Cached Biology News:Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Pilot study shows effectiveness of new, low-cost method for monitoring hand hygiene compliance 2
...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... The F10 tubing kit provides high-pressure ... DuoFlow system and other chromatography systems. ... Teflon, Tefzel, and orange PEEK tubing ... DuoFlow basic chromatography system running at ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
Biology Products: